Following the Ontario provincial government’s announcement on how recreational cannabis will be sold once it becomes legal on October 17, the cannabis industry offered a variety of reactions.
On Monday (August 13), Ontario’s Progressive Conservative government unveiled its approach to the sale of legal adult-use cannabis, saying it will offer consumers online-only service until the establishment of retail shops from private players starting in April 2019.
Minister of Finance Vic Fedeli stated that the provincial government does not intend to be in the business of owning a network of cannabis shops.
Cannabis industry members offer reactions
Charles Taerk, president and CEO of Faircourt Asset Management, said the delay from the provincial government for retail shops has negative implications in the short term.
However, Taerk is optimistic in the long term thanks to the decision by the province to drop the plan of a government monopoly on cannabis shops. The executive also said there is potential for investors to strengthen their positions in companies set to experience declines due to the delay.
“There will likely be some negative trends to the names in the sector as short-term estimates on revenues and earnings are adjusted and moved out 12 months,” Taerk said. “We believe there is likely an opportunity to add to certain positions during this weakness.”
David Clement, a Toronto-based North American affairs manager at the Consumer Choice Center, said the decision by Ontario to embrace private retail is a win for consumers and smart public policy.
Clement added that not having stores with the start of legalization in Canada means consumers will continue to buy cannabis from illegal dispensaries.
“Simply put, relying solely on online sales until April 1 isn’t an accessible enough model to sway people away from the black market,” Clement said. He suggested the province should fast track the application process to allow legal cannabis shops to be available on October 17.
Through its partnership with Alcanna (TSX:CLIQ), Aurora will seek to establish its network of shops across the province once licensing applications become available. In Alberta, the duo already plans to have 37 cannabis shops following legalization.
Toronto-based law firm Aird & Berlis said in an email newsletter that it is interested to see if Ontario will use any of the licensing restrictions planned by other provinces for retail operators.
In Alberta, no person or entity can own more than 15 percent of the retail licenses for the province, while Saskatchewan has a fixed limit of 51 shop permits, according to the law firm.
Stocks take a dive following Ontario’s decision
During Tuesday’s trading session, most of the major cannabis stocks took took a hit from the delay in retail sales for Ontario. Canopy Growth (TSX:WEED,NYSE:CGC) closed with an 8.25-percent decline despite having a clear entry into the retail space with its acquisition of Hiku Brands (CSE:HIKU).
The Horizons Marijuana Growers Index ETF (NEO:HMJR), which tracks small-market-cap cannabis stocks across North America, suffered a 5.68-percent drop, according to the Aequitas Neo Exchange live tracker.
Horizon’s fellow cannabis-focused ETF, the Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ), was also down 4.52 percent at market close on Tuesday. This fund holds close to 40 of the major cannabis stocks in the market.
The Canadian Index from Arcview Group’s Marijuana Index was down 22.33 percent on Tuesday. This index tracks 17 Canadian cannabis stocks like the Hydropothecary Corporation (TSX:HEXO), Organigram Holdings (TSXV:OGI) and Auxley Cannabis Group (TSXV:XLY).
Every listing of the Canadian Index was down on Tuesday, except for CannTrust Holdings (TSX:TRST), which announced its financial results for the second quarter of 2018.
According to Bloomberg, Canaccord Genuity cannabis analyst Matt Bottomley said on Tuesday that the Ontario news will result in a “long-term gain” for cannabis companies and investors.
Canadian licensed producer support group offers response
Avtar Dhillon, board chair for the Cannabis Council of Canada, a group overseeing the interests of licensed producers in Canada, said this move from Ontario will create a “truly competitive and inclusive landscape that will allow for law-abiding companies to more quickly replace the bad apples in the cannabis space.”
The executive director for the association, Allan Rewak, said it removes the cost of brick-and-mortar retail from taxpayers and instead puts it on the private sector to deliver.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: Hiku Brands is a client of the Investing News Network. This article is not paid-for content.
Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry
Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.
Nextleaf Solutions Provides a Corporate Update and Comments on Financial Results from the First Quarter
Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:
Nextleaf Comments on Financial Results from Q1 Financials
Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.
The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.
FinCanna Capital – The Only Publicly Traded, Royalty-Focused Company for the Licensed U.S. Cannabis Industry Provides Corporate Update
Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues
FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million
Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage
Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.